^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Young TIL
i
Other names: Young TIL
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
National Cancer Institute
Drug class:
Immunostimulant
Related drugs:
10ms
Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI... (clinicaltrials.gov)
P2, N=102, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jun 2024 --> Jun 2025
Trial completion date • Trial primary completion date • Metastases
|
cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • Young TIL • ondansetron
10ms
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer (clinicaltrials.gov)
P2, N=332, Recruiting, National Cancer Institute (NCI) | Trial primary completion date: Dec 2023 --> Dec 2024
Trial primary completion date • Metastases
|
Keytruda (pembrolizumab) • cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • Young TIL
1year
A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab (clinicaltrials.gov)
P2, N=20, Suspended, National Cancer Institute (NCI) | N=170 --> 20 | Recruiting --> Suspended
Enrollment change • Trial suspension • Metastases
|
Keytruda (pembrolizumab) • cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • Young TIL
2years
Development of a production process to generate CD8+ T cell-enriched tumor infiltrating lymphocyte (TIL) products with increased cytotoxic potential for the treatment of patients with solid cancers. (ESMO-IO 2022)
The standard 'young TIL' production process using high dose IL-2 and OKT-3 was used as a standard comparison...Conclusions This study shows that CD8 cis-targeted IL-2 can be used to generate TIL products mainly comprising CD8+ T cells, thereby potentially improving cytotoxic potential and therapeutic efficacy. The use of CD3/28 TransAct, compared to anti-CD3 stimulation (OKT-3) improved the final yield of CD8+ T cells in the TIL products.
Clinical • Tumor-Infiltrating Lymphocyte
|
CD8 (cluster of differentiation 8)
|
Young TIL
over2years
A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes (clinicaltrials.gov)
P1, N=6, Terminated, Yale University | N=30 --> 6 | Active, not recruiting --> Terminated; lack of funds
Enrollment change • Trial termination
|
PD-L1 (Programmed death ligand 1) • IL2 (Interleukin 2)
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • cyclophosphamide • Young TIL
Share via
